ZyVersa Therapeutics (ZVSA) AI Stock Analysis

• Market Cap: $1.60M
• Dividend Yield: N/A
• Average Volume (3M): 51.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.63
• Revenue Growth: N/A
• EPS Growth: 88.30%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.56
• Shares Outstanding: 8,095,921
• 10 Day Avg. Volume: 65,792
• 30 Day Avg. Volume: 51,592
• PEG Ratio: <0.01
• Price to Book (P/B): 0.14
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.16
• Enterprise Value/Market Cap: 0.57
• Enterprise Value/Revenue: 35.01
• Enterprise Value/Gross Profit: 70.03
• Enterprise Value/Ebitda: >-0.01
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $0.22 ▲(72.31% Upside)

The score is primarily constrained by very weak financial performance: immaterial revenue, extremely large losses, heavy negative free cash flow, and negative equity. Technicals provide some offset via short-term momentum (price above 20/50/100-day averages with positive MACD), but elevated RSI/Stoch suggests the move is stretched, and valuation remains unattractive due to negative earnings and no indicated dividend yield.

Positive Factors

Low reported leverage

Very low reported debt reduces ongoing interest burdens and preserves borrowing headroom, improving the company’s structural ability to fund clinical programs or negotiate partnerships. Over months this lowers solvency pressure versus highly levered peers when raising capital.

Focused clinical-stage pipeline

A concentrated pipeline in renal and inflammatory indications creates durable strategic focus and technical expertise. Specialized assets (mAb and small-molecule platforms) increase odds of partnering or milestone financing, which can materially de-risk funding needs over a multi-month horizon.

Small positive TTM gross profit

A modest positive gross profit suggests the company can, at least in part, generate margin on product-related activity or recognize revenue with controllable direct costs. If scaled, this structural cost profile could support better long-term unit economics once commercialized.

Negative Factors

Minimal revenue base

Essentially no recurring revenue leaves the business dependent on external financing and makes commercial viability unproven. Over 2-6 months this impairs self-funding of trials, increases dilution risk, and limits operational runway absent new capital or strategic transactions.

Deep cash burn and negative cash flow

Sustained, worsening negative operating and free cash flow creates a structural funding gap that must be filled via equity or partnerships. Persistent cash burn undermines long-term R&D continuity and elevates refinancing risk, pressuring strategic options over months.

Negative equity and diminished capital base

Negative equity indicates capital erosion and reduces financial flexibility: borrowing capacity, counterparty confidence, and partner negotiating leverage are all impaired. Structurally this raises insolvency risk and complicates long-term funding of clinical programs.

ZyVersa Therapeutics Business Overview & Revenue Model

Company Description

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

How the Company Makes Money

ZyVersa Therapeutics makes money primarily through the development and commercialization of its drug candidates. Revenue streams include potential milestone payments and royalties from licensing agreements with pharmaceutical partners. The company may also generate income from collaborations and partnerships aimed at advancing its drug candidates through clinical trials and towards market approval. Additionally, ZyVersa could explore strategic alliances to leverage shared resources and expertise, contributing to its financial growth.

ZyVersa Therapeutics Financial Statement Overview

Summary

Income statement shows immaterial TTM revenue (~$26K) with extremely large operating/net losses and highly negative margins. Cash flow is deeply negative with worsening free cash flow, implying heavy cash burn and financing dependence. Balance sheet has low/near-zero debt, but negative equity in TTM signals significant strain and reduced financial flexibility.

Income Statement

TTM (Trailing-Twelve-Months) revenue is immaterial (~$26K) and profitability is deeply negative, with extremely large operating and net losses and highly negative margins. Annual periods also show no meaningful revenue generation, indicating the business remains pre-commercial and heavily loss-making. Strength is limited to a small positive gross profit in TTM, but it is not enough to offset the large expense base and persistent losses.

Balance Sheet

Leverage is low on paper (total debt reported at or near zero in recent periods), which is a positive. However, equity has turned negative in TTM, signaling balance-sheet strain and reducing financial flexibility; assets are also very small in TTM versus prior years, pointing to a significantly diminished capital base. Earlier years showed positive equity, but the trajectory deteriorates sharply into the most recent period.

Cash Flow

Cash generation is consistently negative, with TTM (Trailing-Twelve-Months) operating and free cash flow both deeply negative and worsening versus the prior period (free cash flow growth is strongly negative). While free cash flow broadly tracks net losses (suggesting losses are largely cash-based rather than accounting-only), the magnitude of cash burn implies ongoing financing dependence and elevated runway/refinancing risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	26.08K	0.00	0.00	0.00	0.00	0.00
Gross Profit	13.04K	-6.93K	-10.40K	-10.40K	-10.40K	-10.40K
EBITDA	-20.76B	-9.14B	-107.74M	-14.43M	-7.25M	-12.16M
Net Income	-19.81B	-9.41B	-98.30M	-14.05M	-8.08M	-12.68M
Balance Sheet
Total Assets	1.04M	20.60M	22.11M	118.51M	1.13M	685.57K
Cash, Cash Equivalents and Short-Term Investments	527.98K	1.53M	3.14M	5.90M	328.58K	174.67K
Total Debt	0.00	0.00	8.66K	108.76K	9.15M	3.82M
Total Liabilities	12.77M	12.08M	11.04M	18.51M	13.63M	9.24M
Stockholders Equity	-11.73M	8.52M	11.07M	99.99M	-12.50M	-8.56M
Cash Flow
Free Cash Flow	-4.70B	-7.56M	-8.72M	-1.49M	-5.08M	-5.11M
Operating Cash Flow	-4.70B	-7.56M	-8.72M	-4.89M	-5.08M	-5.11M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	3.70B	5.95M	5.96M	1.87M	5.23M	4.56M

ZyVersa Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.13
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZVSA, the sentiment is Neutral. The current price of 0.13 is below the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.15, and below the 200-day MA of 0.32, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 54.01 is Neutral, neither overbought nor oversold. The STOCH value of 26.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ZVSA.

ZyVersa Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ZVSA	46 Neutral	$1.60M	-0.04	―	―	―	88.30%
SCNI	43 Neutral	$738.01K	-0.07	―	―	178.82%	-4121.10%